TrialSignal
Clinical trial intelligence report
Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05225961
Status
COMPLETED
Phase
PHASE4
Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Executive brief
Investment-Ready Snapshot
The ATILA trial evaluates the effectiveness and safety of Tirofiban versus intravenous Aspirin in patients with acute ischemic stroke due to tandem lesions, undergoing endovascular treatment. This study aims to establish a protocol for antiplatelet therapy in this patient population, potentially leading to improved outcomes and reduced complications.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05225961
Indication
Acute Ischemic Stroke
Modality
small molecule
Target
Acute Ischemic Stroke
Intervention
Tirofiban, Acetylsalicylic acid
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.